SpringWorks Therapeutics, Inc.
DelistedCIK 1773427fmd_14FMZRGFY0SE9AQ7B8SFBSBNQNManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2018 to Mar 31, 2025, 29 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 35 | 0 | 0 | 5 | 192 |
| Net interest income | – | – | 1 | 1 | 6 | – | – |
| Cost of revenue | – | – | – | 0 | 0 | 0 | 13 |
| Gross profit | – | – | – | 0 | 0 | 5 | 179 |
| Research and development | 10 | 43 | 52 | 102 | 146 | 150 | 201 |
| Selling, general and administrative | – | – | – | 72 | 135 | 198 | 257 |
| Total operating expenses | 18 | 59 | 81 | 173 | 281 | – | – |
| Operating income | (18) | (59) | (46) | (173) | (281) | (343) | (278) |
| Interest and investment income | – | – | – | 1 | 6 | 23 | – |
| Other non-operating income (expense) | 1 | 4 | 1 | 1 | 6 | 23 | 26 |
| Net income | (18) | (58) | (46) | (174) | (277) | (325) | (258) |
| Net income to common shareholders | (18) | (51) | (46) | (174) | (277) | (325) | (258) |